Wedbush Maintains Outperform on IGM Biosciences, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on IGM Biosciences (NASDAQ:IGMS) and raises the price target from $20 to $25.
August 15, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on IGM Biosciences and raises the price target from $20 to $25.
The raised price target and maintained Outperform rating from a reputable analyst at Wedbush is likely to positively impact the stock price of IGM Biosciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100